Professor Eli Schwartz, founder of the Center for Travel Medicine and Tropical Disease at Sheba Medical Center, Tel Hashomer, launched a clinical trial involving ivermectin, the broad-spectrum antiparasitic therapy that absolutely destroyed the novel coronavirus pathogen in an Australian lab experiment. Professor Schwartz undoubtedly has been scanning the use of ivermectin like TrialSite News has been reporting on it: the momentum behind the movement can’t be denied. The drug, Professor Schwartz posits, may be some form of cure.
TrialSite News recently showcased the study in Sheba Medical Center, Israel’s number one health provider and the 9th top health center worldwide. Recently, Schwartz informed The Jerusalem Post that the drug, now tested in mild to moderate cases, launched an investigation to determine if the regimen can significantly shorten the viral shedding period, allowing patients to post negative tests for COVID-19 and hence shorten the isolation period to just a few days. Currently, the infection can last at least two weeks and Gilead’s remdesivir helped reduce this amount by a few days. What if an economical and available drug could do far better?
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).